Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Transferases
Reexamination Certificate
2005-09-06
2005-09-06
Patterson, Jr., Charles L. (Department: 1652)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Transferases
C435S232000
Reexamination Certificate
active
06939541
ABSTRACT:
Histidine ammonia lyase (HAL) isolated from Corynebacteriaceae can decrease serum histidine levels, induce accumulation of urocanic acid, and is not inhibited by L-histidinol. As a result, histidine ammonia lyases similar to the one isolated from Corynebacteriaceae are uniquely suitable for combination therapy with L-histidinol to treat histidine- and/or histamine-dependent pathologies, for example, infectious viruses, such as human Respiratory Syncytial Virus (RSV), Herpes Simplex Virus (HSV), and Human Immunodeficiency Virus (HIV), as well as cancers.
REFERENCES:
patent: 4955857 (1990-09-01), Shettigar
patent: 5824784 (1998-10-01), Kinstler et al.
Rechiler, M.M. (1969) J. Biol. Chem. 244(3), 551-559.
Joseph Roberts et al., Biological and Antineoplastic Effects of Enzyme-Medicated In Vivo Deletion of L- L Glutamine, L-Trytophan, and L-Histidine, Cancer Treatment Reports vol. 63, No. 6, Jun. 1979, pps. 1045-1054.
Holcenberg et al., “Enzymes As Drugs”, Ann. Rev. Pharmacol, Toxicol, 1977 17:97-116, Copyright 1977 by Annuals Reviews Inc.
Shibatani, et al., Cyrstallin L-Histidine Ammonia-Lyase of Achromobacter liquidum Crystallization and Enzymic Properties, Bur J. Biochem, 5, 263-269 (1975.
Wu et al., “Histidine ammonia-lyase fromStreptomcyes griseus”, 1992 Gene- 115, 19-25.
Jack et al., “The Effect of Histidine Ammonia-Lyase On Some Murine Tumours”, Leukemia Research vol., No. 3, pp. 421-429, 1983.
Khanna et al., “Characterization of L-hisstidine ammonia-lyase immobilized by microencapsulation in artifical Cells: preparation, kinetics, stability and in vitro depletion of histidine”, The International Journal of Artifical Organs, vol. 13, No. 3, 1990, pp. 189-195.
Consevage et al., “Sequence Analysis of thebutl-Gene Encoding Histifdine Ammonia-Lyase in Pseudomonas Putidfa”, Journal of Bacteriology, May 1990, 172 pp. 2224-2229.
Oda et al., “Cloning and Nucleotide Sequences of histidase and Regulatory Genes in theBacillus subtilis hutOperon and Positive Regulation of the Operon”, Journal of Bacterology, Jul. 1988, 172, pp. 3199-3205.
Wu et al., “Purification of Histidase fromStreptomyces griseusand Nucleotide Sequence of thehutH Structural Gene”, Journal of Bacteriology, Mar. 1992, 170 pp. 1647-1655.
Taylor et al., “Cloning and Expression of Rat Histidase”, The Journal of Biological Chemistry, vol. 265, No. 30 Oct. 25, pp. 18192-18199, 1990.
Okamura et al., L-Histidine Ammonia-lyase in Rat Liver, J. Biochem, 75, 139-152, 1974.
Watanabe et al., “Induction of Histidine Decarboxylase Activity in Mouse Skin After Application of Indole Alkaloids, A New Class of Tumor Promoter”, Biochemical and Biophysical Research Communications, vol. 109, No. 2, 1982, pp. 478-485.
Bartholeyns et al., “Involvement of Histamine in Growth of Mouse and Rat Tumors: Antitumoral Properties of Monofluoromethylhistidine, and Enzyme-activated Irreversible Inhibitor of Histidine Decarboxylase”, Cancer Research 44, 639-645, Feb. 1984.
Hakii et al., “Thapsigargin, a histamine secretagogue, is a non-12-O-testradecanoylphorbol-13-acetate (TPA) Type tumor promoter in two-stage mouse skin carcinogenesis”, Cancer Research Clinical Oncology, 1986, 111, 88, 177-180.
Mitra et al., “Histamine and Cis-Urocanic Acid Augment Tumor Necrosis Factor-Alpha Mediated Induction of Keratinocyte Intercellular Adhesion Molecular-1 Expression”, Journal of Cellular Physiology 156:348-357, 1993 Wiley-Liss, Inc.
Stolfi et al., “Chemotherapeutic Activity of L-Histidinol against Spontaneous, Autochthonous Murine Breast Tumors”, Chemotherapy 1990, 36:435-440.
Warrington et al., L-Histidinol Reverses Resistance to Cisplatinum and Other Antinneoplastics in a Tumorigenic Epithelial Cell Line, Anticancer Research 16:3641-3646, 1996.
Warrington et al., “Reversal of the Multidrug-Resistant Phenotype of Chinese Hamster Ovary Cells by L-Histidinol”, Journal of the National Cancer Institute, 81, 798-803, (1984).
Warrington et al., “Improved Treatment of Disseminated B16f10 Melanoma in Mice with Anticancer Drugs in Combination with L-Histidinol”, Anticancer Research 11:1869-1874, 1991.
Warrington et al., “Susceptibility of Human Colon Carcinoma Cells to Anticancer Drugs Is Enhanced by L-Histidinol”, Anticancer Research 14:367-372, 1994.
Warrington et al., “L-Histidinol Increases the Vulnerability of Cultured Human Leukemia and Lymphona Cells to Anticancer Drugs”, Anticancer Research 13:2107-2112, 1993.
Warrington et al., “L-Histidinol in experimental cancer chemotherapy: improving the selectivity and efficacy of Anticancer drugs, eliminating metastatic disease and reversing the multidrug-resistant phenotype”, Biochem, Cell Biol., vol. 70, 365-375, 1992.
Zaharko et al., “L-Histidinol: Preclinical Therapeutic Studies in Combination with Antitumor Agents and Pharmacokinetic Studies in Mice”, Cancer Research 52, 3604-3609, Jul. 1992.
Warrington et al., “L-Histidinol Selectively Modulates Daunomycin Toxicity in Normal and Tumorigenic Kidney Epithelial Cells”, Anticancer Research 16:3629-3634, 1996.
Badary et al., “Effect of L-Histidinol on Cisplatin Nephrotoxicity in the Rat”, Neplron (1997) 77, 435-439.
Al-Shabanah et al., “Effects of L-Histidinol On The Antitumor Activity and Acute Cardiotoxicity of Doxorubicin in Mice”, Pharmacological Research, vol., 38 No. 3, 1998, 225-230.
Badary, “L-Histidinol Attenuates Fanconi Syndrome Induced by Ifosfamide in Rate”, (1991) Exp, Nephiol 9, 325-327.
Zaharko et al., “L-Histidinol: Preclinical Therapeutic Studies in Combination with Antitumor Agents and Pharmacokinetic Studies in Mice”, Cancer Research 52, 3604-3609, Jul. 1, 1992.
U.S. Department of Health and Human Services, Hypothermia-Related Deaths, Virginia, Nov. 1996-Apr. 1997, Dec. 12, 1997, vol. 46, No. 49, pp. 1162-1165.
Noonan et al., “Immunosuppression by ultraviolet B radiation: initiation by urocanic acid”, Immunology Today, vol. 13, No. 7, 1992, pp. 250-254.
Altschul et al., “Gapped BLAST and PSA-BLAST: a new generation of protein database search programs”, Nucleic Acids Research, vol. 25, No. 17, 1997, pp. 3389-3402.
Gish et al., “Identificaiton of protein coding regions by database similarity search”, Nature Genetics, vol. 3, 1993, pp. 266-272.
Madden et al., “[9]Applications of Network BLAST Server”, Methods in Enzymology, vol. 266, pp. 131-141.
Altschul et al., “Basic Local Alignment Search Tool”, J. Mol. Biol. vol. 215, 1990, pp. 403-410.
Zhang et al., “PowerBLAST: A New Network BLAST Application for Interactive or Automated Sequence Analysis and Annotation”, Genome Research, vol. 7, 1997, pp. 649-656.
Newman et al., “Selective Killing of Transformed Cells by Methotrexate with Histidine Deprivation or with Amino Alcohols”, Cancer Research vol. 43, Oct. 1983, pp. 4703-4708.
Pardee et al., “Animal Cell Cycle”, Ann. Rev. Biochem, vol. 47, 1978, pp. 715-750.
Pardee, “A Restriction Point for Controll of Normal Animal Cell Proliferation”, Proc. Nat. Acad. Sci., vol. 71, No. 4, 1974, pp. 1286-1290.
Warrington “A Novel Approach for Improving the Efficacy of Experimental Cancer Chemotherapy Using Combinations of Anticancer Drugs and L-Histidinol”, Anticancer Research, vol. 6, 1986, 451-464.
Warrington et al., “L-Histidinol in experimental cancer chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and reversing the multidrug-resistant phenotype”, Biochem. Cell Biol. vol. 7, 1992, pp. 365-375.
Hanson et al., “Epidermaltrans-urocanic acid and the UV-A-induced photaging of the skin”, Proc. Natl. Acad. Sci., vol. 95, 1998, pp. 10576-10578.
Norval, et al., The Role of Urocanic Acid In Un-Induced Immunosuppression: Rec
MacAllister Thomas
Roberts Joseph
Sethuraman Natarajan
Foley & Lardner LLP
Patterson Jr. Charles L.
University of South Carolina
LandOfFree
Cloning, overexpression and therapeutic use of bioactive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cloning, overexpression and therapeutic use of bioactive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cloning, overexpression and therapeutic use of bioactive... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3382705